|Eisai Co. Ltd., of Tokyo||Lenvima (lenvatinib mesylate)||Multikinase inhibitor||Uterine body cancer||Japan’s MHLW granted orphan designation|
|Johnson & Johnson, of New Brunswick, N.J.||Single-dose COVID-19 vaccine||SARS-CoV-2 recombinant adenoviral vector vaccine||COVID-19||European Commission granted conditional marketing authorization, valid in all 27 member states of EU, plus Norway, Iceland and Liechtenstein; World Health Organization also issued emergency use listing for vaccine to prevent COVID-19 in adults, 18 and older|
|Russian Direct Investment Fund, of Moscow||Sputnik V||COVID-19 spike glycoprotein modulator||COVID-19||Vaccine approved by Ministry of Health of the Republic of Azerbaijan|
|Sanofi SA, of Paris||Fabrazyme (agalsidase beta)||Alpha-galactosidase stimulator||Fabry disease||Results from real-world observational study and clinical trial on long-term treatment now included in FDA-approved label|
|Takeda Pharmaceutical Co. Ltd., of Osaka, Japan||Lanadelumab||Monoclonal antibody targeting plasma kallikrein||Hereditary angioedema||Submitted NDA to Japan’s MHLW seeking approval for prophylaxis against HAE attacks|
For more information about individual companies and/or products, see Cortellis.